SEC Form 4 · accession 0001127602-17-017987
GILEAD SCIENCES, INC. · GILD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gayle E Wilson
Director
Period of report
May 10, 2017
Accepted (ET)
May 12, 2017 · 5:48 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000882095
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-qualified Stock Option (Right to Buy)F1 | $66.92 | May 10, 2017 | A | 10,376 | A | — | May 10, 2027 | Common Stock | 10,376 | 10,376 | D |
| Restricted Stock UnitF2,F3 | — | May 10, 2017 | A | 2,241 | A | — | — | Common Stock | 2,241 | 2,241 | D |
Explanation of responses
- F1Options vest quarterly over the first year of service upon the earlier of May 9, 2018, or the day immediately preceding the next regular annual stockholders meeting.
- F2Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.
- F3100% of the restricted stock units will vest upon the earlier of May 9, 2018, or the day immediately preceding the next regular annual stockholders meeting.